Dajun Yang, Ph.D., is the Co-Founder, Chairman of the Board, and Chief Executive Officer of Ascentage Pharma. He has over 20 years of experience in cancer research and drug development and has co-founded and managed several biotech companies. Prior to founding Ascentage, Dr. Yang co-founded US Ascenta Therapeutics in 2003, where he was a Senior Vice President of Research and Preclinical Development. In 2005, Dr. Yang established the Ascenta R&D Center in Shanghai and served as the first General Manager and as a member of its Board of Directors. Earlier, Dr. Yang built the biology and pharmacology team for S*BIO Pte Ltd, a Singapore-Chiron joint venture for which he served as the first Vice President of Biology. He was also a Managing Director for Morningside Venture Groups, a biotechnology- and healthcare-focused fund, and served as President & CEO of Stealth Peptides Inc. From 2002-2005, Dr. Yang also served as an Associate Professor of Internal Medicine in the Comprehensive Cancer Center at the University of Michigan. He was an Associate Professor of Biochemistry and Molecular Biology (June 1995 to June 1999) and Oncology (July 1999 to May 2001), and a Senior Investigator of the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center. During his career, Dr. Yang has also taught part-time and supervised doctoral students at the Comprehensive Cancer Center of Sun Yat-sen University.
Dr. Yang is the author or co-author of 92 publications and the inventor of 14 patents. He was a co-founder, chief staff writer and editor for two national magazines in China, namely “Chinese Medical Students” and “Family Doctors”. Nowadays “Family Doctors” has a monthly publication volume of over one million and it has the mission to promote both healthcare and a healthy lifestyle in China.
Dr. WANG Shaomeng, Ph.D., is the co-founder of Ascentage Pharma and has been appointed as its chairman of the Scientific Advisory Board since 2010. Dr. Wang joined the University of Michigan in July 2001 as a tenured faculty and is currently a Warner-Lambert/Parke Davis Professor in Medicine at University of Michigan, Ann Arbor, where he also serves as the co-director of the experimental therapeutics program at the University of Michigan Comprehensive Cancer Center (the Rogel Cancer Center) and director of the Michigan Center for Therapeutic Innovation. Dr. Wang was also appointed as the editor-in-chief of the Journal of Medicinal Chemistry since 2011, and was re-appointed to the same role in 2015.
Dr. Wang obtained his Bachelor’s degree in Chemistry from Peking University in July 1986. He received his Ph.D. degree from Case Western Reserve University in Chemistry in the United States in January 1993.
Dr. TIAN Yuan, Ph.D., the founding partner of YuanMing Capital, was appointed as as non-executive Director of Ascentage Pharma on August 15, 2018. He is also appointed as a member of the remuneration committee of the Company. Prior to joining Ascentage, Dr. Tian established China International Futures Corporation (a PRC-based company mainly engaged in futures investment business) in 1992 and served as the chairman from 1992 to 2007. He also served as the chairman of China Chengtong Holdings Group Limited (a company primarily engaged in integrated logistics service, assets operation and management in the PRC) from 1997 to 2002. Dr. Tian is the founder of, and has been serving as the chairman of China Entrepreneurs Forum since 2001 and China-US Business Leaders Roundtable since 2010. He has also served as the chairman of Investment Committee of China Pharmaceutical Industry Research and Development Association since 2018. He is the recipient of the China Economics Theory Innovation Award in 2011. Since June 2018, he has served as a member on the Biotech Advisory Panel of the Stock Exchange, and he is responsible for providing advice to assist the Stock Exchange in its review of listing applications from biotech companies when being consulted by the Stock Exchange.
Dr. Tian obtained his Master’s degree and Doctoral degree in Economics from Wuhan University in September 1983 and August 1992, respectively.
Mr. ZHAO Qun, MBA, is a partner at SIP Oriza Seed Fund Management Co., Ltd., a venture capital investment firm. Prior to that, he served as a senior investment manager at SIP Oriza PE Fund Management. From October 2006 to February 2012, he worked at Shanghai Tasly Pharmaceutical Co., Ltd, and his last position was deputy manager. From January 1998 to October 2006, Mr. Zhao worked at Tasly Pharmaceutical Group Co., Ltd., and his last position was the manager of its quality assurance department. Mr. Zhao graduated with a Bachelor’s degree in Pharmaceutical Analysis from China Pharmaceutical University, and received his Executive Master of Business Administration from Nankai University.
Dr. LU Simon Dazhong, Ph.D., MBA, has more than 18 years of experience in the investment and consulting business. He is a Managing Director of SIDC Fund Management Company Ltd., a China-based private equity fund manager. From January 2008 to July 2009, Dr. Lu served as the Managing Director and a member of the investment committee of CEL Partners, a private equity firm. From September 2002 to December 2007, he was a partner of Shanghai Newmargin Ventures, a venture capital management company. Dr. Lu has also served as a securities analyst at China International Capital Corporation Limited, and as a financial analyst at Scotiabank in Toronto, Canada. Early in his career, he worked as an auditor and audit and business consulting supervisor at Arthur Andersen in Shanghai and Chicago. Dr. Lu graduated with a Bachelor of Economics from Nankai University, his Master of Business Administration from McGill University in Canada, and Ph.D. in Economics degree from Nankai University.
Mr. LIU Qian, MBA, has been the Chief Investment Officer of Prudence Investment Management, a Hong Kong-based investment management company, since December 2008. He worked as a Director and trader in Global Markets at Deutsche Bank from October 2006 to December 2008, and prior to that, Mr. Liu worked for Morgan Stanley Investment Management, including as an Executive Director and portfolio manager. He graduated with a Bachelor’s degree in Economics from Wuhan University, and received his Master’s degree in Business Administration from the Wharton School of the University of Pennsylvania.
Mr. YE Changqing has over 25 years of experience in professional accounting, financial advisory and investment. Mr. Ye obtained a Bachelor’s degree in Journalism from Huazhong University of Science and Technology in July 1992, and a Master’s degree in Business Administration from the University of Warwick in the United Kingdom in November 1999. Mr. Ye has been a Certified Public Accountant of the PRC since December 1994.
Dr. YIN Zheng, Ph.D., is the Executive Director and Manager of Sany. Innova (Beijing) Investment Management Co. Since August 2018, he has been serving as the Executive Director and Manager of Sany. Innova (Beijing) Investment Management Co., Ltd. He joined SDIC Fund Management Co., Ltd. as Executive Director and then Managing Director responsible for the pharma/biotech sector between August 2016 and July 2018. Prior to that, Dr. Yin worked as Vice Dean (July 2009-November 2011) and then Dean (November 2011-April 2015) of the School of Pharmacy at Nankai University. He also served as a professor at Tsinghua University. Earlier, Dr. Yin worked as Principal Scientist at Novartis Institute for Tropical Diseases Pte. Ltd., and as a research scientist at S*Bio Pte. Ltd. Dr. Yin obtained a Bachelor’s degree and Master’s degree in Science from Nankai University. He obtained his Doctoral degree in Chemistry from National University of Singapore.
Mr. REN Wei has over 15 years of legal experience covering onshore and offshore securities issues, China-related mergers & acquisitions and foreign investment. He is a Partner at Jingtian & Gongcheng and has been with the firm since 2003. Mr. Ren has been a Director of Beijing Dongcheng District State-owned Assets Administration Commission since January 2018. Mr. Ren obtained a Bachelor’s degree in Law and a Bachelor’s degree in Economics both from Peking University. He has been qualified to practice law in China.
Known for in research in biomarkers for early detection and therapy and profiled by TIME magazine in 2001 as one of America’s best in science and medicine, Dr. Sidransky is a leading expert in oncology and precision medicine widely respected in the biopharmaceutical industry. Dr. Sidransky is currently the Director of the Head and Neck Cancer Research Division at Johns Hopkins University School of Medicine’s Department of Otolaryngology; and Professor of Oncology, Cellular & Molecular Medicine, Urology, Genetics, and Pathology at the Johns Hopkins University School of Medicine. Dr. Sidransky is also serving as a member on the Scientific Advisory Boards of numerous professional organizations and institutions, including the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), and the National Cancer Institute (NCI) of the U.S. Having authored over 550 peer-reviewed publications, contributed 45 cancer reviews and chapters, and invented 28 biotechnology patents, Dr. Sidransky is one of the world’s most highly cited researchers in clinical and medical journals.
Dr. Sidransky has accumulated immense industry experience and exceptional expertise, not only in scientific research, but also in business operations, corporate governance and investment strategies. Dr. Sidransky is a founder of a number of biotechnology companies such as Champions Oncology (Nasdaq; CSBR). Previously, Dr. Sidransky was Vice Chairman of ImClone Systems Inc., a global biopharmaceutical company committed to advancing oncology care, until its acquisition by Eli Lilly. Dr. Sidransky is also a Co-Founder and Managing Partner of the Israel Biotech Fund. Furthermore, Dr. Sidransky is a highly-experienced board member, after having served as a director on the boards of Galmed Pharmaceuticals (Nasdaq: GLMD), Orgenesis (Nasdaq: ORGS), Advaxis (Nasdaq: ADXS), and Ayala (Nasdaq: AYLA).